Aptevo raises $2.1M in registered direct offering and private placement; existing warrants amended

Aptevo Therapeutics Inc.

Sold 1,764,710 shares of common stock and warrants to purchase up to 3,529,420 shares at $1.19/unit.
Gross proceeds ~$2.1M; net proceeds ~$1.9M after fees; Roth Capital acted as placement agent.
Amended existing Dec 2024 warrants: exercise price reduced from $9.53 to $1.19 per share.
Exercise of new and amended warrants requires stockholder approval; warrants expire 5 years from approval date.
Proceeds for clinical development of product candidates and working capital.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.